MECHANISM OF ACTION
TARGET INTERLEUKIN 5 (IL-5) WITH NUCALA
The mechanism of action of mepolizumab in EGPA has not been definitively established.
Following subcutaneous administration of NUCALA 300 mg every 4 weeks for 52 weeks, in subjects with EGPA:
- Blood eosinophils were reduced by 83% compared with placebo
- This magnitude of reduction was observed within 4 weeks of treatment
- The clinical significance of these data is unknown